. Author manuscript; available in PMC: 2016 Mar 29.

Published in final edited form as: Int J Cancer. 2012 Mar 28;131(9):2008–2015. doi: 10.1002/ijc.27493

Table 1.

Incidence of neoplasms in the livers of male B6C3F₁ mice administered 0.14 or 0.70 mmol acrylamide or glycidamide per kg body weight, or the vehicle, intraperitoneally on PNDs 1, 8, and 15

Liver neoplasm	Treatment (mmol acrylamide or glycidamide per kg body weight)
	Control	Acrylamide		Glycidamide
	0.0	0.14	0.70	0.14	0.70
Hepatocellular adenoma	1/26^a (3.8%)^b	2/24 (8.3%)	1/24 (4.2%)	2/24 (8.3%)	2/21 (9.5%)
Hepatocellular adenoma, multiple	0/26 (0.0%)	0/24 (0.0%)	0/24 (0.0%)	0/24 (0.0%)	13/21 (61.9%)^*
Hepatocellular adenoma, singular or multiple	1/26 (3.8%)	2/24 (8.3%)	1/24 (4.2%)	2/24 (8.3%)	15/21 (71.4%)^*
Hepatocellular carcinoma	0/26 (0.0%)	0/24 (0.0%)	0/24 (0.0%)	0/24 (0.0%)	2/21^c (9.5%)
Hepatocellular adenoma or carcinoma	1/26 (3.8%)	2/24 (8.3%)	1/24 (4.2%)	2/24 (8.3%)	15/21 (71.4%)^*

Number of mice with the specified neoplasm per number of mice examined microscopically.

Percentage of mice with the specified neoplasm.

Two mice had both an adenoma and carcinoma.

Significantly different (p < 0.0001) from the incidence observed in the vehicle control group.